A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice

Robert Bod&eacute;n,1,2 Gunnar Edman,3,4 Johan Reutfors,2 Claes-G&ouml;ran &Ouml;stenson,3 Urban &Ouml;sby3,4 1Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden; 2Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Insti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bod&eacute;n R, Edman G, Reutfors J, &Ouml;stenson CG, &Ouml;sby U
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/409632f52b8649e08e6a97a2ede8cf30
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:409632f52b8649e08e6a97a2ede8cf30
record_format	dspace
spelling	oai:doaj.org-article:409632f52b8649e08e6a97a2ede8cf302021-12-02T07:52:50ZA comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice1176-63281178-2021https://doaj.org/article/409632f52b8649e08e6a97a2ede8cf302013-03-01T00:00:00Zhttp://www.dovepress.com/a-comparison-of-cardiovascular-risk-factors-for-ten-antipsychotic-drug-a12508https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Robert Bod&eacute;n,1,2 Gunnar Edman,3,4 Johan Reutfors,2 Claes-G&ouml;ran &Ouml;stenson,3 Urban &Ouml;sby3,4 1Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden; 2Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden; 3Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; 4Department of Psychiatry, Tiohundra AB, Norrt&auml;lje, Sweden Abstract: It is well known that abdominal obesity, dyslipidemia, and insulin resistance are highly prevalent in patients receiving maintenance treatment with antipsychotics, but there is limited knowledge about the association between cardiovascular risk factors and treatment with antipsychotic drugs. In this naturalistic study we investigated a sample of 809 antipsychotic-treated patients from Swedish psychosis outpatient teams. Cardiovascular risk factors (eg, metabolic syndrome, homeostasis model assessment of insulin resistance, and low-density lipoprotein values) were measured, and their associations to current antipsychotic pharmacotherapy were studied. Ten antipsychotic drugs were compared in a stepwise logistic regression model. For the patients, the presence of the components of metabolic syndrome ranged from 35% for hyperglycemia to 64% for elevated waist circumference. Hypertriglyceridemia was associated with clozapine (odds ratio [OR] = 1.81, 95% confidence interval [CI] 1.08&ndash;3.04), reduced high-density lipoprotein with both clozapine and olanzapine (OR = 1.73, 95% CI 1.01&ndash;2.97; and OR = 2.03, 95% CI 1.32&ndash;3.13), hypertension with perphenazine (OR = 2.00, 95% CI 1.21&ndash;3.59), and hyperglycemia inversely with ziprasidone (OR = 0.21, 95% CI 0.05&ndash;0.89) and positively with haloperidol (OR = 2.02, 95% CI 1.18&ndash;3.48). There were no significant relationships between any of the antipsychotic drugs and increased waist circumference, homeostasis model assessment of insulin resistance, or low-density lipoprotein levels. In conclusion, treatment with antipsychotic drugs is differentially associated with cardiovascular risk factors, even after adjusting for waist circumference, sex, age, and smoking. Keywords: adverse metabolic effects, antipsychotic drugs, cardiovascular risk factors, HOMA-IR, metabolic syndromeBod&eacute;n REdman GReutfors J&Ouml;stenson CG&Ouml;sby UDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 371-377 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Bod&eacute;n R Edman G Reutfors J &Ouml;stenson CG &Ouml;sby U A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
description	Robert Bod&eacute;n,1,2 Gunnar Edman,3,4 Johan Reutfors,2 Claes-G&ouml;ran &Ouml;stenson,3 Urban &Ouml;sby3,4 1Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden; 2Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden; 3Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; 4Department of Psychiatry, Tiohundra AB, Norrt&auml;lje, Sweden Abstract: It is well known that abdominal obesity, dyslipidemia, and insulin resistance are highly prevalent in patients receiving maintenance treatment with antipsychotics, but there is limited knowledge about the association between cardiovascular risk factors and treatment with antipsychotic drugs. In this naturalistic study we investigated a sample of 809 antipsychotic-treated patients from Swedish psychosis outpatient teams. Cardiovascular risk factors (eg, metabolic syndrome, homeostasis model assessment of insulin resistance, and low-density lipoprotein values) were measured, and their associations to current antipsychotic pharmacotherapy were studied. Ten antipsychotic drugs were compared in a stepwise logistic regression model. For the patients, the presence of the components of metabolic syndrome ranged from 35% for hyperglycemia to 64% for elevated waist circumference. Hypertriglyceridemia was associated with clozapine (odds ratio [OR] = 1.81, 95% confidence interval [CI] 1.08&ndash;3.04), reduced high-density lipoprotein with both clozapine and olanzapine (OR = 1.73, 95% CI 1.01&ndash;2.97; and OR = 2.03, 95% CI 1.32&ndash;3.13), hypertension with perphenazine (OR = 2.00, 95% CI 1.21&ndash;3.59), and hyperglycemia inversely with ziprasidone (OR = 0.21, 95% CI 0.05&ndash;0.89) and positively with haloperidol (OR = 2.02, 95% CI 1.18&ndash;3.48). There were no significant relationships between any of the antipsychotic drugs and increased waist circumference, homeostasis model assessment of insulin resistance, or low-density lipoprotein levels. In conclusion, treatment with antipsychotic drugs is differentially associated with cardiovascular risk factors, even after adjusting for waist circumference, sex, age, and smoking. Keywords: adverse metabolic effects, antipsychotic drugs, cardiovascular risk factors, HOMA-IR, metabolic syndrome
format	article
author	Bod&eacute;n R Edman G Reutfors J &Ouml;stenson CG &Ouml;sby U
author_facet	Bod&eacute;n R Edman G Reutfors J &Ouml;stenson CG &Ouml;sby U
author_sort	Bod&eacute;n R
title	A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
title_short	A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
title_full	A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
title_fullStr	A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
title_full_unstemmed	A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
title_sort	comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/409632f52b8649e08e6a97a2ede8cf30
work_keys_str_mv	AT bodampeacutenr acomparisonofcardiovascularriskfactorsfortenantipsychoticdrugsinclinicalpractice AT edmang acomparisonofcardiovascularriskfactorsfortenantipsychoticdrugsinclinicalpractice AT reutforsj acomparisonofcardiovascularriskfactorsfortenantipsychoticdrugsinclinicalpractice AT ampoumlstensoncg acomparisonofcardiovascularriskfactorsfortenantipsychoticdrugsinclinicalpractice AT ampoumlsbyu acomparisonofcardiovascularriskfactorsfortenantipsychoticdrugsinclinicalpractice AT bodampeacutenr comparisonofcardiovascularriskfactorsfortenantipsychoticdrugsinclinicalpractice AT edmang comparisonofcardiovascularriskfactorsfortenantipsychoticdrugsinclinicalpractice AT reutforsj comparisonofcardiovascularriskfactorsfortenantipsychoticdrugsinclinicalpractice AT ampoumlstensoncg comparisonofcardiovascularriskfactorsfortenantipsychoticdrugsinclinicalpractice AT ampoumlsbyu comparisonofcardiovascularriskfactorsfortenantipsychoticdrugsinclinicalpractice
_version_	1718399097451315200

A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice

Ejemplares similares